September 1996 - Zyprexa receives FDA approval for schizophrenia
2000 – Zyprexa receives FDA approval for bipolar disorder
May 2002 - Britain's Medicines Control Agency warns that several patients taking Eli Lilly's top selling drug Zyprexa (used to treat schizophrenia) had developed diabetes-related complications. In the Medicine Control Agency's Current Problems newsletter, the regulatory body said that Zyprexa "can adversely affect blood glucose." Forty reports of hyperglycemia (elevated blood sugar), diabetes mellitus, or exacerbation of diabetes have been received in the UK. Four were associated with ketoacidosis and/or coma including one with a fatal outcome.
April 2002 - The Japanese Health and Welfare Ministry issues an emergency warning to Eli Lilly Japan KK concerning side effects of Zyprexa following the deaths of two diabetic users of the drug. The Ministry said seven other patients had lost consciousness or become comatose after taking the drugs in the previous 10 months.
2002 - Study at Duke University showed a connection between Zyprexa and diabetes. This study documented nearly 300 cases of diabetes in people using Zyprexa.
2003 - the FDA requested that Eli Lilly and Company update its product labeling for Zyprexa to include a warning about hyperglycemia and diabetes.
April 11, 2005 – FDA warns that older patients with dementia given Zyprexa at greater risk of dying prematurely
April 12, 2005 – Black box warning added to Zyprexa label
June 2005 – Eli Lilly announces plans to settle Zyprexa claims
Use of Zyprexa Has Been Linked to Diabetes | YOU HAVE RIGHTS
Free Case Review
NEW YORK
626 RexCorp Plaza
Uniondale, NY 11556
p: (516) 333-1415
f: (516) 333-1838
BOSTON
60 State Street,
Suite 700
Boston, MA 02109
p: (617) 742-7700
f: (617) 371-2950